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CASE REPORT
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Key Clinical Message
This report highlights zonisamide as a potential cause of serious cutaneous
reactions as well as its cross-reactivity with other sulfonamides. Here, we present a case of SJS-TEN due to zonisamide, which was effectively treated with
IVIg. Subsequently, the patient was transitioned to levetiracetam for seizure
control.
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Here, we present the youngest patient with SJS-TEN
overlap syndrome secondary to zonisamide.

Introduction
Zonisamide is a second-generation antiepileptic drug
(AED) that was approved by the U.S. Food and Drug
Administration in 2000 as an adjunctive therapy for partial
seizures in adults with epilepsy [1]. It was first used in
Japan starting in the 1970s as a psychiatric medication and
later in Japan and Korea in the 1990s for treatment of seizures. As a synthetic 1,2-benzisoxazole-3-methanesulfonamide, zonisamide is chemically related to atypical, secondgeneration antipsychotic agents like risperidone as opposed
to the first-generation AEDs such as carbamazepine [2].
The use of zonisamide as an antiepileptic agent in both
children and adults has been increasing after it was
demonstrated to be as effective as first-generation AEDs
for the treatment of partial epilepsy [3]. Zonisamide is
also being used as off-label monotherapy and adjunctive
therapy for psychiatric disorders such as alcohol abuse,
bipolar disorder, and binge-eating disorder [4]. Advantages of zonisamide, particularly in the pediatric population, include its once-daily dosing (divided dosing can be
used if needed), being relatively well tolerated, being unlikely to react with other medications, and not requiring
serum level measurements [3, 5].
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Case Report
A 2-year-old African American girl with a past medical
history of extreme prematurity born at 25 weeks of gestational age and seizure disorder was transferred to our
hospital with a rash for 1 day, with associated conjunctival injection and crusting around the eye. The mother
reported that the girl did not want her skin to be
touched, possibly secondary to pain. The mother also
reported fever, decreased appetite, and decreased energy.
There was no prior history of a similar rash. The patient
had no rhinorrhea, cough, or congestion. Her medication
history was significant for a change from levetiracetam to
zonisamide for seizure control about two and a half weeks
prior to presentation. Neurology had recommended the
change for improved seizure control and for improved
adherence since zonisamide was once-daily dosing. The
patient did not have any other new medications including
antibiotics within the past month prior to presentation.
On physical examination, the patient was afebrile and
difficult to console. She had erythematous targetoid
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macules, papules, and plaques with dusky centers on her
face, neck, chest, abdomen, back, bilateral upper extremities, and bilateral lower extremities involving 75% body
surface area (BSA). Nikolsky sign was positive in 9% BSA
upon presentation, and the rash progressed within 24 h
to approximately 20% BSA Nikolsky positive. Tense bullae were noted on her face, arms, and legs with sloughing
on the left upper arm at site of prior bandage. Mucosal
lesions included erosions and crusting of her lips, conjunctival injection, and erythema and erosions of her labia
minora (Figs 1 and 2).
Biopsies for frozen section and permanent pathology
revealed full-thickness epidermal necrosis with a pauciinflammatory infiltrate (Fig. 3). Herpes simplex virus and
varicella zoster virus polymerase chain reaction tests from
a bulla were negative. Laboratory studies revealed significant transaminitis with alanine aminotransferase (ALT) of
891 U/L and aspartate aminotransferase (AST) of 595 U/
L. Alkaline phosphatase was also elevated at 304 IU/L.
Complete blood count, electrolytes, and kidney function
were within normal limits. Respiratory viral panel, hepatitis A immunoglobulin M (IgM) antibody, hepatitis B core
IgM antibody, hepatitis B surface antigen, and hepatitis C
antibody were negative. Serum urea, bicarbonate, and glucose levels were within normal limits. The patient was
admitted to the pediatric intensive care unit with the
diagnosis of Stevens–Johnson syndrome/toxic epidermal
necrolysis overlap. Her severity of illness scale for toxic
epidermal necrolysis (SCORTEN) was one [6].
Zonisamide was discontinued immediately, and intravenous immunoglobulin (IVIg, 1 g/kg/day) for 3 days
was administered without complications. Neurology
restarted the patient on levetiracetam for her seizure disorder. Her skin improved significantly over the next
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Figure 2. Clinical photograph of patient’s bullae and full-thickness
epidermal desquamation.

Figure 3. Biopsy specimen demonstrating full-thickness epidermal
necrosis, 100X.

2 weeks, and at the time of discharge, only mild crusting
of her lips remained with all other cutaneous lesions
healed. Her transaminitis resolved during admission as
well.

Discussion

Figure 1. Clinical photograph of patient demonstrating dusky,
erythematous macules, and papules as well as crusting and erosions
of the lips.
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To our knowledge, this is the second case of SJS-TEN
overlap syndrome associated with zonisamide reported in
the United States [7].
Though usually well tolerated, common side effects of
zonisamide include dizziness, sedation, headache, weight
loss, decreased appetite, and decreased bicarbonate levels

259

K. L. Vivar et al.

Zonisamide-induced SJS/TEN

[3, 8]. Rashes occur in up to 2% of patients treated with
zonisamide and may be more common in patients receiving zonisamide in combination with first-generation
AEDs [9, 10]. Serious cutaneous reactions include druginduced hypersensitivity syndrome, SJS, and TEN [9].
The incidence of SJS/TEN in the setting of zonisamide
is not known. In the United States, the only reported case
was a 16-year-old female adolescent with bipolar disorder
who was switched from valproic acid to zonisamide secondary to weight gain. After 2 weeks of zonisamide, she
developed a painful, bullous eruption and was diagnosed
with TEN. This patient’s mother reported being allergic
to sulfa medications [7]. In addition, one case of SJS was
reported in a postmarketing surveillance study of 1938
patients treated with zonisamide who were followed for at
least twelve weeks [8]. Other details of the case were not
published. Teraki et al. reported a 71-year-old man who
was initially on valproate sodium for epilepsy and then
started on zonisamide for seizure recurrence. Twentythree days after initiation of the zonisamide, the patient
developed a targetoid, blistering eruption consistent with
TEN. Interestingly, IgG titers and human herpesvirus 6
(HHV6) DNA levels in the patient’s blood increased over
the progression of his eruption, suggesting HHV6 reactivation [11]. The other reported cases come from case series in Japan, where 13 patients with epilepsy were taking
zonisamide and developed SJS/TEN. Three of the patients
were taking zonisamide in combination with one aromatic antiepileptic such as phenytoin or carbamazepine.
There were five females and eight males in this group.
The median age of these patients was 52 years old, ranging from 6 to 71 years old. The average time to development of SJS/TEN was about 23 days [12].
In the two cases reported in detail in the literature and
our case reported here, all three patients developed TEN
within 2–4 weeks of starting zonisamide. Additionally, all
cases were on zonisamide as monotherapy after prior
exposure to another agent, either valproic acid or levetiracetam. Notably, our patient was the youngest to
develop SJS/TEN in the setting of zonisamide. IVIg was
used effectively in the case reported by Teraki et al. as
well as in the present case. The third case by Majeres and
Suppes did not report management.
Given the increasing use of zonisamide for neurological
and psychiatric disorders, it has become important to
determine the risk of potentially fatal cutaneous reactions
such as SJS/TEN. Prior use of levetiracetam or valproic
acid may play a role in predisposing to TEN. Family history of sulfa allergy may also be clinically significant [7].
In Japan, where zonisamide has been prescribed for a
longer period than in the United States, studies have
shown that HLA-A*02:07 may be a biomarker for susceptibility to zonisamide-induced SJS/TEN [12].
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Additionally, a study of in vitro cross-reactivity
between zonisamide and either sulfonamides or first-generation AEDs underscores the chemical relatedness of
zonisamide to sulfa medications. Lymphocyte toxicity
assays (LTAs) from 20 patients with known DIHS to sulfamethoxazole demonstrated cross-reactivity between sulfonamides and zonisamide. In contrast, LTAs from 20
patients with known DIHS to first-generation AEDs did
not cross-react with zonisamide [9]. Especially in light of
recent case reports of HHV6 reactivation in SJS/TEN
patients, classically thought of in DIHS, future studies
may evaluate whether LTAs can also be used to predict
SJS/TEN secondary to zonisamide [11, 13].
In sum, the risk of SJS/TEN associated with zonisamide
appears to be low but real. The incidence of these serious
and life-threatening cutaneous eruptions due to zonisamide needs to be further investigated. The development
of screening tests such as HLA typing and LTAs may also
identify at-risk patients. Clinicians should maintain high
clinical suspicion in order to promptly discontinue the
culprit drug and initiate appropriate intensive inpatient
SJS/TEN management including diligent wound care,
fluid and electrolyte management, and systemic therapies
like steroids, intravenous immunoglobulin, or other
immunomodulators. Importantly, clinicians should also
be aware of the cross-reactivity of zonisamide with other
sulfa medications in order to counsel patients to avoid all
sulfa medications in the future.
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